Try Fund Library Premium

For Free with a 30 day trial!

Gain access to

  • Unlimited Watchlists
  • Advanced Search Filtering
  • Fund Comparisons
  • Portfolio Scenarios
  • Customizable PDF Reports

RBC Life Science and Technology Fund Series A

U.S. Equity

FundGrade A Click for more information on Fundata’s FundGrade

FundGrade A

Click for more information on Fundata’s FundGrade.

Fundata ESG GradeB Click for more information on Fundata’s ESG Grade

Fundata ESG Grade B

Click for more information on Fundata’s ESG Grade.

FundGrade A+® Rating Recipient

FundGrade A+® Rating Recipient

2024, 2023, 2022, 2021, 2020

Click for more information on Fundata’s FundGrade

NAVPS
(12-05-2025)
$64.46
Change
-$0.34 (-0.53%)

As at October 31, 2025

As at September 30, 2025

As at October 31, 2025

Period
Loading...

Legend

RBC Life Science and Technology Fund Series A

Compare Options


Fund Returns

Inception Return (July 31, 1995): 8.74%

Fund Returns
Row Heading Return Annualized Return
1 Mth 3 Mth 6 Mth YTD 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 9 Yr 10 Yr
Fund 5.83% 13.87% 35.21% 18.74% 26.45% 33.52% 30.07% 16.26% 18.73% 20.03% 19.00% 17.99% 18.82% 16.97%
Benchmark 3.05% 9.59% 25.45% 14.49% 22.34% 30.15% 23.77% 15.58% 18.85% 17.51% 17.07% 16.09% 16.39% 15.44%
Category Average 2.01% 6.67% 20.13% 10.14% 15.07% 24.02% 18.33% 10.24% 14.39% 13.11% 12.81% 11.81% 12.39% 11.36%
Category Rank 49 / 1,388 10 / 1,372 53 / 1,340 76 / 1,303 107 / 1,302 148 / 1,252 70 / 1,172 43 / 1,105 61 / 1,059 33 / 995 41 / 917 47 / 852 37 / 764 40 / 687
Quartile Ranking 1 1 1 1 1 1 1 1 1 1 1 1 1 1

Monthly Return

Monthly Return
Return % Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct
Fund 4.13% 2.27% 3.31% -3.51% -8.81% -3.40% 6.50% 6.66% 4.52% 0.49% 7.08% 5.83%
Benchmark 6.59% 0.26% 3.46% -1.62% -6.04% -4.57% 5.88% 4.21% 3.75% 1.28% 5.00% 3.05%

Best Monthly Return Since Inception

37.88% (February 2000)

Worst Monthly Return Since Inception

-21.85% (February 2001)

Calendar Return (%)

Calendar Return
Return % 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fund 21.81% -0.84% 22.08% 8.77% 25.94% 29.23% 24.97% -22.89% 37.42% 37.19%
Benchmark 20.77% 8.65% 13.80% 3.98% 25.18% 16.07% 28.16% -12.52% 23.32% 36.01%
Category Average 10.40% 6.16% 13.43% -2.19% 22.72% 13.97% 23.22% -14.41% 18.85% 26.98%
Quartile Ranking 1 4 1 1 2 1 2 4 1 1
Category Rank 84/ 640 595/ 689 109/ 767 90/ 853 305/ 925 136/ 999 421/ 1,064 895/ 1,111 106/ 1,173 233/ 1,259

Best Calendar Return (Last 10 years)

37.42% (2023)

Worst Calendar Return (Last 10 years)

-22.89% (2022)

Asset Allocation

Asset Allocation
Name Percent
US Equity 93.81
International Equity 4.17
Cash and Equivalents 1.25
Canadian Equity 0.79

Sector Allocation

Sector Allocation
Name Percent
Technology 73.89
Healthcare 15.80
Consumer Services 3.32
Telecommunications 1.81
Industrial Goods 1.47
Other 3.71

Geographic Allocation

Geographic Allocation
Name Percent
North America 95.85
Europe 3.29
Latin America 0.68
Asia 0.20

Top Holdings

Top Holdings
Name Percent
NVIDIA Corp 10.85
Microsoft Corp 10.08
Alphabet Inc Cl A 8.78
Apple Inc 8.66
Meta Platforms Inc Cl A 5.94
Broadcom Inc 5.20
Netflix Inc 2.07
Eli Lilly and Co 2.04
Oracle Corp 1.85
Abbvie Inc 1.83

Equity Style

Market capitalization is large. Equity style is growth.

Fixed Income Style

Fixed income style data not available
Period: 

Risk vs Return (3 Yr)

RBC Life Science and Technology Fund Series A

Median

Other - U.S. Equity

3 Yr Annualized

Standard Deviation 14.35% 15.70% 15.02%
Beta 1.10% 1.08% 1.08%
Alpha 0.03% -0.01% 0.00%
Rsquared 0.80% 0.85% 0.84%
Sharpe 1.65% 1.01% 1.00%
Sortino 3.10% 1.58% 1.51%
Treynor 0.21% 0.15% 0.14%
Tax Efficiency 100.00% 100.00% 100.00%
Volatility Volatility rating is 9 on a scale of 1 to 10 Volatility rating is 9 on a scale of 1 to 10 Volatility rating is 9 on a scale of 1 to 10

Risk Rating

Rating 9 out of ten

Annualized Key Ratio Period Comparison

Key Ratio
Key Ratio 1 Yr 3 Yr 5 Yr 10 Yr
Standard Deviation 17.28% 14.35% 15.70% 15.02%
Beta 1.15% 1.10% 1.08% 1.08%
Alpha 0.01% 0.03% -0.01% 0.00%
Rsquared 0.86% 0.80% 0.85% 0.84%
Sharpe 1.29% 1.65% 1.01% 1.00%
Sortino 2.11% 3.10% 1.58% 1.51%
Treynor 0.19% 0.21% 0.15% 0.14%
Tax Efficiency 100.00% 100.00% 100.00% 100.00%

Fundata ESG Metrics

Fundata ESG Score

The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.

Fundata E Score

Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.

Fundata S Score

Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.

Fundata G Score

Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.

Powered by OWL Analytics. For more information, please contact Fundata Canada.

Fund Details

Start Date July 31, 1995
Instrument Type Mutual Fund
Share Class Commission Based Advice
Legal Status Trust
Sales Status Open
Currency CAD
Distribution Frequency Annual
Assets ($mil) $2,967

Fund Codes

FundServ Code Load Code Sales Status
RBF274

Investment Objectives

The objective of the fund is to provide long-term capital growth. The fund invests primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

Investment Strategy

The fund’s investment process is primarily based on fundamental research, although the portfolio manager will also consider quantitative and technical factors. Stock selection decisions are ultimately based on an understanding of the company, its business and its outlook. Life science investments include biotechnology, medical devices and services, pharmaceuticals and medical instruments.

Portfolio Management

Portfolio Manager

RBC Global Asset Management Inc.

  • Rob Cavallo
  • Marcello Montanari
Sub-Advisor

-

Management and Organization

Fund Manager

RBC Global Asset Management Inc.

Custodian

RBC Investor Services Trust (Canada)

Registrar

RBC Global Asset Management Inc.

Royal Bank of Canada

RBC Investor Services Trust (Canada)

Distributor

Royal Mutual Funds Inc.

Investment Minimums

RSP Eligible Yes
PAC Allowed Yes
PAC Initial Investment 25
PAC Subsequent 25
SWP Allowed Yes
SWP Min Balance 10,000
SWP Min Withdrawal 100

Fees

MER 2.05%
Management Fee 1.75%
Load No Load
FE Max -
DSC Max -
Trailer Fee Max (FE) -
Trailer Fee Max (DSC) -
Trailer Fee Max (NL) 1.00%
Trailer Fee Max (LL) -

Try Fund Library Premium

For Free with a 30 day trial!

Gain access to

  • Unlimited Watchlists
  • Advanced Search Filtering
  • Fund Comparisons
  • Portfolio Scenarios
  • Customizable PDF Reports